SkinBioTherapeutics has provided a business update covering its lead products, AxisBiotix-Ps and SkinBiotix. The second phase of the launch of AxisBiotix-Ps was initiated in February, with a direct-to-consumer strategy including the use of social media influencers with psoriasis who are using the product. While the impact of the second phase will take several weeks to assess, the board believes our revenue forecast of £1.2m remains achievable for FY22E. Croda continues to make progress with Skin ....
17 Feb 2022
Cenkos: SkinBioTherapeutics Plc -- Business update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: SkinBioTherapeutics Plc -- Business update
SkinBioTherapeutics Plc (SBTX:LON) | 9.2 0 0.0% | Mkt Cap: 18.5m
- Published:
17 Feb 2022 -
Author:
Chris Donnellan -
Pages:
6
SkinBioTherapeutics has provided a business update covering its lead products, AxisBiotix-Ps and SkinBiotix. The second phase of the launch of AxisBiotix-Ps was initiated in February, with a direct-to-consumer strategy including the use of social media influencers with psoriasis who are using the product. While the impact of the second phase will take several weeks to assess, the board believes our revenue forecast of £1.2m remains achievable for FY22E. Croda continues to make progress with Skin ....